.... This effect may be overcome by administering agents that are converted to 5-FU or by inhibiting or inactivating DPD. Xeloda ® (capecitabine) was designed as an orally administered, selectively tumoractivated TM cytotoxic agent which achieves higher levels of 5-FU in the primary tumor than in plasma or other...

...Jim Cassidy For over four decades, 5-fluorouracil (5-FU) has been the mainstay of therapy for colorectal cancer and a major cytotoxic agent for treating gastrointestinal tumors and a variety of others, including breast and head and neck cancers. Xeloda ® (capecitabine) is a new drug...

... access to hospital is limited by financial considerations, long journeys or patient reluctance. In the past, only alkylating agents (cyclophosphamide, chlorambucil, melphalan) could be administered orally. The activity (first- and second-line) of Xeloda ® (capecitabine) with limited side effects...

...Joanne L. Blum There are few treatment options available for patients with metastatic breast cancer who have failed anthracycline- and paclitaxel-based chemotherapy. Xeloda ® (capecitabine) is a novel selectively tumoractivated TM fluoropyrimidine carbamate producing clinically active levels of 5...

...Jaap Verweij 5-Fluorouracil (5-FU) plays an important role in the treatment of several tumor types, particularly colorectal cancer and breast cancer. Xeloda ® (capecitabine; 5′-deoxy-5-fluoro-N-[(pentyloxy)carbonyl-cytidine]) is a new rationally designed fluoropyrimidine carbamate...